AbbVie (WBO:ABBV) Inventories, Finished Goods : €1,157 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AbbVie Inventories, Finished Goods?

AbbVie's quarterly finished goods increased from Sep. 2023 (€970 Mil) to Dec. 2023 (€1,243 Mil) but then declined from Dec. 2023 (€1,243 Mil) to Mar. 2024 (€1,157 Mil).

AbbVie's annual finished goods increased from Dec. 2021 (€825 Mil) to Dec. 2022 (€1,097 Mil) and increased from Dec. 2022 (€1,097 Mil) to Dec. 2023 (€1,243 Mil).

AbbVie Inventories, Finished Goods Historical Data

The historical data trend for AbbVie's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Inventories, Finished Goods Chart

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

436.50

1,083.40

824.82

1,096.93

1,243.45

AbbVie Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															1,231.95	1,086.37	969.80	1,243.45	1,157.36

AbbVie Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

AbbVie (WBO:ABBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV34:Brazil

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.